Our Approach


We have a robust pipeline of programs to prevent disease progression, improve outcomes and protect against organ damage in cardiorenal diseases.



Therapeutic Areas

We have developed a robust portfolio of products that act by activating multiple cytoprotective pathways. Learn more about our approach and the conditions we are treating below.

Cardiothoracic surgery represents a significant burden to the US healthcare system with over 294,000 coronary artery bypass graft (CABG) and valve replacement/repair procedures performed annually.

CABG the most common cardiothoracic surgical procedure in the US accounts for $6.5 billion in health care costs annually making it one of the most expensive surgical procedures in the United States.

ICU is a standard component of postoperative care following cardiothoracic surgery however the longer the patient stays in ICU results in increased hospital morbidity and mortality, poor long-term prognosis, increased hospital stays, and consequently increased cost and expenses. Most ICU therapies post cardiothoracic surgery are only supportive and therefore may not individually result in improved outcomes.

Cardiac surgery techniques have improved considerably however up to 36% of patients undergoing cardiothoracic surgery are still exposed to a high risk of postoperative complications.

These postoperative complications include longer patient days in the intensive care unit (ICU), increase ventilator days, acute kidney injury and an increase in the 30-day hospital readmission rate.

–  More than 36% of patients undergoing cardiac surgery have a long (> 36 hours) postoperative stay in ICU.

–  This results in failure of some organs and an increase in the mortality rate.

Failure to rescue (FTR) is defined as patient mortality after a post cardiothoracic surgery complication that occurred before hospital discharge.

–  Early failure to rescue increases as the number of postoperative complications increased 7.5%, 28.1%, and 51.5% for one, two, and three or more complications, respectively.

–  FTR rates were highest among those with combined prolonged ventilation and renal failure at 38.4%.

– Length of intensive care unit stay varied by number of postoperative complications with the median number of intensive care unit hours ranging from 38 hours for patients with no complications to 358.5 hours for patients with at least three complications.

– Overall median length of stay ranged from 7 days for patients with no complications to 22.5 days for patients with at least three complications.
The average cost of CABG surgery without complications is approximately $36,580.

The additive cost effects of complications after cardiothoracic surgery are:

– Prolonged ventilation (>24 h) +$33,840
– Renal failure +$33,847
– Reoperation +$35,239

Prolonged ventilation incurs the highest health system expenditures given its high incidence and the accumulation of multiple complications increase costs exponentially.

– 30 million people or approximately 15% of U.S. Adults have CKD. (CDC 2017)

– Almost one out of every 7 adults 30-64 years of age is expected to develop CKD during their lifetime

– While dialysis-dependent CKD accounts for only 0.5% of the U.S. population, fee-for-service expenditures for Medicare beneficiaries with dialysis-dependent CKD exceeded 30 billion dollars in 2013, or over 7% of the Medicare paid claims cost

– Escalation in healthcare expenditures associated with CKD starts prior to the requirement for dialysis and treatment cost escalate as non-dialysis dependent CKD progresses

– CKD is a significant unmet medical need, and the financial burden has reached insurmountable proportions for patients and the U.S. healthcare system. In 2018, Medicare costs were $119 billion, and similar public cost burdens likely exist in the EU and Asia.